Each Friday, we provide an update on the current live tracking portfolio (as of the previous day’s closing prices), a summary of the last week of trading activity, and updates on any significant developments among the companies we have positions in.
In looking at the distressed-bond market today, Marty Fridson suggests: Fasten your seatbelts. It’s going to get very bumpy. But investors who remain rational will profit extravagantly from the foreseeable disconnect between value and price in the lower-quality end of the corporate bond market.
There are good AI stocks and there are not-so-good AI stocks: some are overvalued and some are growing revenue and earnings while creating lasting innovations. It is a stock market where both things can be true.
Each Friday, we provide an update on the current live tracking portfolio (as of the previous day’s closing prices), a summary of the last week of trading activity, and updates on any significant developments among the companies we have positions in.
In the Distressed Investing April 10 report, “Car Talk,” we recommended buying Cerence AI’s 1.5% convertible bond maturing July 1, 2028. Today, we recommend selling the bond. At the time of the recommendation, the bond was priced at $692, which equated to annual yield of 13.6%. We indicated that we thought it extremely unlikely that
In the May 8 Distressed Investing report, “Cracking the Code,” we recommended the combined $1,000 purchase of one Green Plains 2.25% convertible bond, then trading at $774, and shares of Green Plain stock (Nasdaq: GPRE), then trading at $3.66. At the time this equated to one bond and 61.7 shares. Recently we recommended selling the
Shares of liquefied natural gas (“LNG”) exporter Venture Global (NYSE: VG), which we recommended in The Big Secret On Wall Street, fell 20% today on an adverse ruling in its arbitration case against oil giant BP. The case deals with LNG supply contracts between the two companies during 2022, when LNG prices shot up following
Each Friday, we provide an update on the current live tracking portfolio (as of the previous day’s closing prices), a summary of the last week of trading activity, and updates on any significant developments among the companies we have positions in.
If you’ve missed out on Bitcoin’s and Ethereum’s meteoric rise, this month’s issue of Tech Frontiers is for you. If you’ve ridden these meteors, congratulations – this issue will offer you a thoughtful way to diversify your gains and stay onboard.
Shares of the Tech Frontiers July recommendation, Prime Medicine (Nasdaq: PRME), are trading at around $6.37 today, a gain of over 100% from our entry price of $3.07 three months ago. As a result, we recommend selling half your position. Prime is making terrific progress advancing its gene-editing platform and we have many reasons for